124 related articles for article (PubMed ID: 22773795)
21. The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment.
Thomas X; Heiblig M
Expert Opin Drug Discov; 2016 Nov; 11(11):1061-1070. PubMed ID: 27548716
[TBL] [Abstract][Full Text] [Related]
22. Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives.
Malagola M; Papayannidis C; Baccarani M
Ann Hematol; 2016 Apr; 95(5):681-93. PubMed ID: 26891878
[TBL] [Abstract][Full Text] [Related]
23. Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.
Bleckmann K; Schrappe M
Br J Haematol; 2016 Mar; 172(6):855-69. PubMed ID: 26773444
[TBL] [Abstract][Full Text] [Related]
24. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
Lilly MB; Ottmann OG; Shah NP; Larson RA; Reiffers JJ; Ehninger G; Müller MC; Charbonnier A; Bullorsky E; Dombret H; Brigid Bradley-Garelik M; Zhu C; Martinelli G
Am J Hematol; 2010 Mar; 85(3):164-70. PubMed ID: 20131302
[TBL] [Abstract][Full Text] [Related]
25. TKIs may be option for Ph-like ALL.
Cancer Discov; 2014 Dec; 4(12):1359-60. PubMed ID: 25477088
[TBL] [Abstract][Full Text] [Related]
26. Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Thomas X; Dombret H
Leuk Lymphoma; 2008 Jul; 49(7):1246-54. PubMed ID: 18452076
[TBL] [Abstract][Full Text] [Related]
27. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Pfeifer H; Wassmann B; Pavlova A; Wunderle L; Oldenburg J; Binckebanck A; Lange T; Hochhaus A; Wystub S; Brück P; Hoelzer D; Ottmann OG
Blood; 2007 Jul; 110(2):727-34. PubMed ID: 17405907
[TBL] [Abstract][Full Text] [Related]
28. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
Abou Dalle I; Kantarjian HM; Short NJ; Konopleva M; Jain N; Garcia-Manero G; Garris R; Qiao W; Cortes JE; O'Brien S; Kebriaei P; Kadia T; Jabbour E; Ravandi F
Am J Hematol; 2019 Dec; 94(12):1388-1395. PubMed ID: 31595534
[TBL] [Abstract][Full Text] [Related]
29. Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL.
Riva G; Luppi M; Lagreca I; Barozzi P; Quadrelli C; Vallerini D; Zanetti E; Basso S; Forghieri F; Morselli M; Maccaferri M; Paolini A; Fantuzzi V; Messerotti A; Maffei R; Iacobucci I; Martinelli G; Marasca R; Narni F; Comoli P; Potenza L
Br J Haematol; 2014 Jan; 164(2):299-302. PubMed ID: 24134676
[No Abstract] [Full Text] [Related]
30. Complicated and Advanced Atherosclerosis in a Young Woman With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Success and Challenges of BCR/ABL1-Targeted Cancer Therapy.
Herrmann J; Bell MR; Warren RL; Lerman A; Fleming MD; Patnaik M
Mayo Clin Proc; 2015 Aug; 90(8):1167-8. PubMed ID: 26250733
[No Abstract] [Full Text] [Related]
31. Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Swords R; Alvarado Y; Giles F
Clin Lymphoma Myeloma; 2007 Mar; 7 Suppl 3():S113-9. PubMed ID: 17382020
[TBL] [Abstract][Full Text] [Related]
32. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
[TBL] [Abstract][Full Text] [Related]
33. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
[TBL] [Abstract][Full Text] [Related]
34. Two cases of acute lymphoblastic leukemia with an e1a3 BCR-ABL1 fusion transcript.
Shin SY; Cho JH; Kim HJ; Jang JH; Lee ST; Kim SH
Ann Lab Med; 2015 Jan; 35(1):159-61. PubMed ID: 25553301
[No Abstract] [Full Text] [Related]
35. BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside.
Boer JM; den Boer ML
Eur J Cancer; 2017 Sep; 82():203-218. PubMed ID: 28709134
[TBL] [Abstract][Full Text] [Related]
36. [New therapeutic strategy for Philadelphia chromosome-positive acute lymphoblastic leukemia].
Usui N
Rinsho Ketsueki; 2006 Apr; 47(4):294-302. PubMed ID: 16715964
[No Abstract] [Full Text] [Related]
37. Pharmacologic inhibition of the Bcr-Abl kinase with STI571: a novel, safe, and effective therapy for chronic myeloid leukemia.
Press RD
Mol Diagn; 2001 Sep; 6(3):211-3. PubMed ID: 11571715
[No Abstract] [Full Text] [Related]
38. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
[TBL] [Abstract][Full Text] [Related]
39. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
[TBL] [Abstract][Full Text] [Related]
40. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.
Hofmann WK; Komor M; Wassmann B; Jones LC; Gschaidmeier H; Hoelzer D; Koeffler HP; Ottmann OG
Blood; 2003 Jul; 102(2):659-61. PubMed ID: 12663457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
